PIK3CA inhibitors demonstrated satisfactory activity in breast carcinomas, but showed low efficacy in non-breast cancer clinical trials; it is essential to acknowledge that the BC trials involved the combination of PIK3CA with endocrine therapy, while other studies utilized single-agent PIK3CA inhibition [101,102,103]. Here, PIK3CA is linked to breast cancer.